Saxenda is currently only prescribed to patients with a BMI ≥35 (≥32.5 if BAME background) who also have non-diabetic hyperglycaemia (pre-diabetes), and either hypertension or dyslipidaemia.
Other weight management medications such as Wegovy are not currently available due to supply issues with GLP-1 medications and referrals specifically for consideration of others will not be accepted for this reason. This is an area likely to change with changes to national policy and this criteria will be reviewed to reflect that in due course. It is very likely that the supply of Saxenda will also be affected in the near future.
